1. Department of Cardiology, Amsterdam University Medical Center, Amsterdam, the Netherlands; 2. Department of Cardiology, Toho University medical center Ohashi hospital, Tokyo, Japan; 3. Department of Internal Medicine, Cardiology Division, University of Campinas (UNICAMP), Campinas, Brazil; 4. Thoraxcenter, Erasmus University Medical Center, Rotterdam, the Netherlands; 5. First Department of Cardiology, Subdivision of Interventional Cardiology, Medical University of Warsaw, Warsaw, Poland; 6. Boston Scientific, Marlborough, MA, USA; 7. Department of Internal Medicine, Discipline of Cardiology, University of Triangulo Mineiro, Uberaba, MG, Brazil; 8. Unicor, Linhares, ES, Brazil; 9. Heart Institute (InCor), University of Sao Paulo, Sao Paulo, Brazil; 10. Icahn School of Medicine at Mount Sinai, New York, NY, USA; 11. Imperial College London, London, United Kingdom
Introduction
The ASET (Acetyl Salicylic Elimination Trial) pilot study (NCT03469856) is designed to evaluate the hypothesis that a single antiplatelet therapy with prasugrel starting immediately after the procedure is feasible and safe in patients selected after successful percutaneous coronary intervention (PCI) with new-generation biodegradable polymer drug-eluting stent (DES) implantation.
Methods
STUDY DESIGN
The ASET pilot study is designed as a multicentre, single-arm, open-label, proof-of-concept pilot trial. Based on previous pilot studies with similar designs, a sample of 200 patients will be enrolled from 12 centres in Brazil with a stopping rule based on the occurrence of definite ...
Sign in to read and download the full article
Forgot your password?No account yet? Sign up for free!
Create my pcr account Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com
Coronary interventionsStable CADStents and scaffolds
Read next article
Derivation and external validation of a novel risk score for prediction of 30-day mortality after percutaneous coronary intervention